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Abstract
Traumatic brain injury (TBI) is an important cause of disability and mortality in the western world. While the initial
injury sustained results in damage, it is the subsequent secondary cascade that is thought to be the significant
determinant of subsequent outcomes. The changes associated with the secondary injury do not become irreversible
until some time after the start of the cascade. This may present a window of opportunity for therapeutic interventions
aiming to improve outcomes subsequent to TBI. A prominent contributor to the secondary injury is a multifaceted
inflammatory reaction. The complement system plays a notable role in this inflammatory reaction; however, it has
often been overlooked in the context of TBI secondary injury. The complement system has homeostatic functions in
the uninjured central nervous system (CNS), playing a part in neurodevelopment as well as having protective functions
in the fully developed CNS, including protection from infection and inflammation. In the context of CNS injury, it can
have a number of deleterious effects, evidence for which primarily comes not only from animal models but also, to a
lesser extent, from human post-mortem studies. In stark contrast to this, complement may also promote neurogenesis
and plasticity subsequent to CNS injury. This review aims to explore the role of the complement system in
TBI secondary injury, by examining evidence from both clinical and animal studies. We examine whether
specific complement activation pathways play more prominent roles in TBI than others. We also explore the
potential role of complement in post-TBI neuroprotection and CNS repair/regeneration. Finally, we highlight
the therapeutic potential of targeting the complement system in the context of TBI and point out certain
areas on which future research is needed.
Background
Traumatic brain injury (TBI) is a leading cause of morbid-
ity in the developed world, with an estimated 1.5–2 million
Americans suffering from TBI each year and 52,000 dying
as a consequence of TBI per year [1]. While medical
advancements, including improvements in pre-hospital
and critical care, have contributed greatly to a reduction in
TBI-related mortality [2], it is still a leading cause of
disability in the developed world, and a significant number
of those who suffer from a TBI-related disability may
require lifetime care. TBI is defined as damage to the brain
resulting from an external force that causes the brain to
move quickly within the skull. The damage that results is
associated with an altered mental state. TBI can be classi-
fied as impact or non-impact. Impact TBI occurs when the
head is involved in a direct impact with an object. Non-
impact TBI occurs when there is no direct contact
between the head and another object, but the head is still
exposed to a force, as may occur in acceleration-
deceleration injuries. TBI can also be classified on the basis
of severity, according to the Glasgow Coma Scale (GCS),
as mild, moderate or severe [3].
The initial mechanical impact associated withTBI results
in a primary injury, subsequent to which a delayed second-
ary injury, normally develops [4]. This secondary injury is
thought to be an important determinant of outcomes [5].
Thus, there may be a window of opportunity, between the
start of the secondary injury cascade and the time at which
these secondary changes become irreversible, during which
medical intervention (e.g. pharmacologically) may improve
outcomes. A major contributor to the secondary injury is
neuroinflammation [6]. Microglia resident within the
central nervous system (CNS) have been proposed to exist
in two main states (M1 and M2), depending on the
balance between pro- and anti-inflammatory mediators in
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the CNS milieu [7], though this view has been recently
challenged (e.g. [8]). Pro-inflammatory mediators are
believed to favor the M1 phenotype, with M1 microglia
playing a crucial role in the clearance of cell debris as well
as foreign antigens. However, M1 microglia can also result
in damage to healthy cells, as well as releasing further pro-
inflammatory mediators that can perpetuate and
exacerbate the inflammatory reaction [9, 10]. In contrast,
anti-inflammatory mediators are thought to favor the M2
phenotype, which is associated with improved cellular sur-
vival and tissue repair [11, 12]. Moreover, in vitro evidence
suggests that M2 microglia are able to promote neurite
outgrowth [13, 14]. Microglia express receptors for various
complement components, including C1q and C3 cleavage
products, and thus the complement system plays a crucial
role in microglial activation [15]. In pathological states
with blood–brain barrier (BBB) compromise, there is evi-
dence that C1q contributes to a shift towards the M1
phenotype [16]. Mannose-binding lectin (MBL), part of
the lectin pathway of complement activation, also appears
to contribute to microglial activation, perhaps by promot-
ing fibrin deposition [17]. It is thought that both M1 and
M2 phenotype switching occurs in TBI, but it appears that
there is a bias towards M1 over M2 in TBI secondary
injury [7, 13]. In addition to the direct damage induced by
M1 microglia, the aforementioned pro-inflammatory
cytokines they release can activate astrocytes [10]. While
reactive astrocytes can have some protective effects in the
CNS, e.g. through the release of neurotrophic factors [7,
18, 19], the major result of astrocytic activation is the
formation of glial scars [10]. Glial scars function as barriers
to axonal regeneration and extension [7]. The initial injury
also compromises the BBB, which permits the entry of per-
ipheral circulating leukocytes, thereby further enhancing
the inflammatory response [20, 21]. A major component
of the inflammatory response that is often overlooked, the
complement system, is also activated as part of the neu-
roinflammatory response in TBI [22–24]. The endogenous
CNS complement system is activated, and its activation is
further enhanced by an influx of complement components
from the circulation, aided by the breakdown of the BBB.
In addition to the neuroinflammatory response, the sec-
ondary injury in TBI is associated with a number of other
changes that contribute to damage. Firstly, hypoperfusion
of the penumbral region surrounding the core injury
occurs. Thus, there is a mismatch between the metabolic
requirements of cells in the penumbra and the cerebral
blood flow to this area [25]. This mismatch disrupts the
sodium-potassium (Na+-K+) pumps present in neuronal
cell membranes, which results in transient depolarization
of the cell membrane. Depolarization induces glutamate
release [26], which can lead to excitotoxic neuronal death
[27]. Excitotoxicity is associated with a rise in intracellular
calcium ([Ca2+]i), which activates a number of enzymes
(e.g. proteases, phospholipases and endonucleases) that
can damage the cell [28]. The rise in [Ca2+]i also enhances
the generation of free radicals, which can bring about fur-
ther damage, including mitochondrial damage that can
further exacerbate the oxidative stress [29].
This review will focus particularly on the role the
complement system plays during TBI secondary injury.
The complement system is now thought to have both
deleterious effects and neuroprotective effects in the
CNS, and this review will explore the balance between
them in the context of TBI secondary injury. The review
will also explore the literature concerning attempts to
modulate the complement system in the context of TBI
secondary injury to explore whether this has had any
impact on post-injury outcomes.
Overview of the complement system
The complement system is traditionally viewed as part
of the innate immune system that, along with the adap-
tive immune system, is involved in protecting the body
from foreign antigens [30]. It encompasses more than 30
proteins (both cell surface-bound and soluble) that are
zymogens. There is significant amplification in the
cascade, as once these zymogens have been activated,
the resulting active enzymes can then go on to repeat-
edly act on their substrates [31].
The complement system can be activated via any one of
three different pathways: the classical, alternative and
lectin pathways [32] (see Fig. 1). Another pathway that
can lead to complement activation is the extrinsic pathway
of the coagulation cascade [33]. The classical pathway is
activated by C1q binding to the fragment crystallizable
(Fc) region of IgG and/or IgM antibodies bound to anti-
gens to which they are reactive. C1r and C1s then bind to
C1q to form a C1qrs complex, with the C1s component
cleaving C4 to C4a and C4b, and C2 to C2a and C2b. C2b
can subsequently associate with C4b to form C4bC2b,
which functions as a C3 convertase. The C3 convertase
cleaves C3 to C3a and C3b, with C3a being an anaphyla-
toxin. Anaphylatoxins can induce histamine release from
mast cells, smooth muscle contraction and can increase
vascular permeability. They are also involved in mediating
chemotaxis. C3b is an opsonin, which enhances the
phagocytosis of apoptotic cells and pathogens. The lectin
pathway also generates the same C3 convertase, but via a
different mechanism. In this pathway, bacterial carbohy-
drate motifs are bound by MBL. MBL-associated serine
proteases (MASPs) then cleave C4 and C2, generating
C4bC2b. The alternative pathway, like the classical path-
way, leads to continuous tickover of complement (i.e. its
activation at a low background rate). In this pathway, C3
reacts with water to produce C3(H2O). Factors B (fB) and
D (fD) are then recruited, with fD cleaving fB to generate
fBb. fBb can bind to C3b to generate the alternative
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pathway C3 convertase, C3bBb. The regulator properdin
is able to stabilise this convertase [34]. Both convertases,
C3bBb and C4b2b, can recruit further C3b molecules and
form complexes with them. These complexes, C3bBbC3b
and C4b2bC3b, function as C5 convertases. This results in
the formation of C5a (which is another anaphylatoxin)
and C5b. The formation of C5b can initiate the formation
of the membrane attack complex (MAC), by binding to
C6, C7, C8 and 10–16 C9 molecules to form C5b-9. The
resulting MAC complex can insert into the membranes of
cells, resulting in the lysis of non-nucleated cells as well as
having milder effects on nucleated cells [31, 35]. C5a is a
powerful pro-inflammatory molecule, augmenting the
production of various chemokines, cytokines, reactive
oxygen species (ROS) as well as mediators such as prosta-
glandins. It is also capable of acting as a chemoattractant,
by upregulating leukocyte adhesion molecules on endo-
thelial cells, thereby enhancing the extravasation of leuko-
cytes into foci of inflammation and/or infection [36]. The
complement system also appears to take part in regulating
the adaptive immune system, including both T cells and B
cells. There is evidence that complement contributes to
the regulation of T cell activation and proliferation [37,
38]. Similarly, complement facilitates the activation of B
cells and enhances the survival of memory B cells [39–41].
In addition to extracellular complement activation, it
has become apparent that the complement cascade can
be activated intracellularly too [42, 43]. Human T helper
cells store C3 intracellularly. They also contain cathepsin
L (CTSL) and C3a receptors (C3aRs). CTSL cleaves C3,
generating C3a and C3b. C3a then binds to C3aRs,
which has an important function in T cell survival [44].
Since this discovery was made, it has emerged that T
cells also possess intracellular C5 stores [43]. Intracellu-
lar C5 is cleaved by an as yet unidentified enzyme to
generate C5a. C5a can then bind to C5 a receptor 1
(C5aR1), which results in inflammasome activation as
well as increased production of ROS by T cells [45].
The activation of the complement system must be tightly
regulated, in order for it to only be activated when re-
quired (i.e. in the presence of a foreign antigen) and so that
it is not erroneously activated (see Fig. 2). A number of
mechanisms exist that regulate the activity of the conver-
tases. One such mechanism involves decay accelerating
factor (DAF), which accelerates the breakdown of both C3
and C5 convertases associated with the cell membrane
[46], thereby also interfering with MAC formation [47].
Similarly, serum factor I (fI) in concert with membrane
cofactor protein (MCP) acts to cleave C3b to iC3b, which
inactivates the C3 convertase [48]. The final mechanism
that acts at the C3 convertase stage involves factor H (fH),
which binds to C3b attached to the cell membrane and ac-
celerates its breakdown [49]. Further mechanisms that are
involved in complement regulation include the inhibition
Fig. 1 Schematic illustration of the complement cascade. The three activation pathways, the classical, alternative and lectin (MBL) pathways, are
all included. Shown are the anaphylatoxins (C3a and C5a), which can trigger mast cell degranulation, and the MAC, which can lead to cell lysis.
Adapted from Mathern and Heeger, 2015 [28]
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of MAC formation by CD59, and the inhibition of the clas-
sical and lectin pathways by C1 inhibitor (C1-INH). CD59
is believed to inhibit MAC formation by blocking the
polymerization of C9 and its association with C5b678 [49].
The complement system in the healthy CNS
Given that the brain and spinal cord are surrounded by
the BBB and blood–spinal cord barrier (BSB), respectively,
it would be expected that circulating plasma complement
components should be mostly excluded from the CNS.
However, it has been known for a long time that compo-
nents of the complement cascade are present within the
CNS [50], with a number of studies demonstrating that
both neurons and glial cells are capable of synthesizing
them [51, 52]. Similarly, a number of studies have shown
that complement receptor expression is widespread within
the CNS, with mRNA encoding receptors for C3a and
C5a being expressed widely [53–55].
The complement system plays a number of vital roles in
brain homeostasis [56]. Complement is involved in the
clearance of cellular debris as well as cells undergoing
apoptosis [56]. It is also thought to play a role in the clear-
ance of amyloid β (Aβ) plaques, deposition of which is asso-
ciated with ageing and Alzheimer’s disease, via opsonization
of the deposited proteins thereby rendering them more
susceptible to phagocytosis by resident microglia [57].
Moreover, the complement system has been implicated in
protecting the CNS from infection and inflammation. Ex-
periments carried out in a murine model of pneumococcal
meningitis have demonstrated that mice lacking either of
complement components C1q or C3 are more susceptible
to Streptococcus pneumoniae infections affecting the CNS
compared to controls [58]. Similarly, C3a/glial fibrillary
acidic protein (C3a/GFAP) mice, which have restricted
overexpression of C3a in the CNS, were less susceptible to
mortality subsequent to endotoxin/LPS-induced shock than
wildtype and C3a receptor (C3aR) deficient mice [59]. In
support of these observations, bacterial infection and/or
inflammation were found to lead to the upregulation of
complement mRNA expression in the CNS [60, 61].
More recently, further roles for the complement system
in the CNS under physiological conditions, including
Fig. 2 Illustration of the different mechanisms regulating the complement cascade. a DAF accelerates the decay of cell surface-assembled classical
and alternative pathway C3 and C5 convertases. b CD59 inhibits MAC formation. c fH accelerates the breakdown of membrane-bound C3b. d fI, in
concert with MCP, which irreversibly cleaves C3b to iC3b, thereby inactivating it. e C1 inhibitor is a protease that inactivates C1r, C1s and
mannose-binding lectin-associated serine proteases (MASPs), which irreversibly prevents reformation of the classical and MBL pathways initiating complexes.
Adapted from Mathern and Heeger, 2015 [28]
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developmental functions, have been revealed [56]. Evi-
dence that complement is involved in synaptic pruning
during development came primarily from murine studies
on the development of the retinogeniculate pathway.
These studies demonstrated that complement compo-
nents C1q and C3, released by astrocytes, opsonize synap-
ses that are to be eliminated thereby rendering them more
susceptible to phagocytosis by microglia [62–64]. C1q−/−,
C3−/− and C4−/− mice all possessed excess synapses and
showed reduced synaptic pruning compared to wildtypes
[62, 65, 66]. C1q knockout (C1q−/−) mice have a greater
incidence of epileptogenesis than wildtypes, as indicated
both by epileptiform activity on electroencephalogram
(EEG) as well as behavioral seizure activity [64]. Comple-
ment also appears to be involved in cerebellar develop-
ment, for which there is evidence from experiments in
neonatal rats. It was found that the expression of both
C3aRs and C5a receptors (C5aRs) increased postnatally in
cerebellar granule cells, reaching a peak on postnatal day
12 (P12) [67]. Moreover, administration of a C3aR agonist
to neonatal rats was associated with an increase in the
thickness of the internal granule cell layer and a concomi-
tant decrease in the thickness of the external granule cell
layer. This suggests that C3a might normally be involved
in facilitating granule cell migration from the external to
the internal granule cell layer. In contrast, C5aR agonist
administration was associated with an increase in the
thickness of the external granule cell layer. It was also
associated with enhanced survival of granule cells, second-
ary to a reduction in the activity of caspase-9, which func-
tions as an apoptosis initiator [67, 68].
The complement system and CNS injury
When the CNS is subjected to an insult that results in
injury, a cascade of secondary pathophysiological events is
induced, a key part of which is a prominent neuroinflam-
matory response. These secondary events compromise the
integrity of the neurons present in the penumbral region,
which would not have been directly affected by the
primary insult to the injured core [69]. Much attention
has been directed at the role of the adaptive immune
response in secondary injury (e.g. [70]), but there has been
more recent interest in the complement system as an
important player in secondary injury [71, 72].
Clinical studies
Traumatic injuries to both the brain and spinal cord are
accompanied by a breakdown of the BBB and BSB, re-
spectively. Therefore, in addition to the fairly low levels
of complement components expressed endogenously in
the brain/spinal cord, there is a massive influx of serum
proteins, including complement components (see Table 1
for a summary). There is also an influx of various innate
and adaptive immune cells that are able to contribute to
complement activation [69]. The complement system
appears to play a particularly significant role in the sec-
ondary injury that occurs in the context of TBI. Frontal
and temporal lobes resected from TBI patients were
probed by immunohistochemistry for the presence of
complement components. It was found that the levels of
C1q, C3b, C3d and MAC were elevated in the penum-
bral regions of the injured area compared to controls
[23]. Similar results were observed in animal models of
TBI [22]. These findings were supported by the observa-
tion that a number of complement components, e.g. C3,
C1q and fB, were raised in the cerebrospinal fluid (CSF)
of TBI patients compared to controls [73, 74]. Similarly,
MAC levels were significantly raised in the CSF of TBI
patients compared to controls [24]. Moreover, MBL
immunostaining in TBI patients was observed around
blood vessels in brain tissue that had undergone TBI
injury, with no staining observed in controls [75].
Animal studies
Evidence for complement involvement in TBI secondary
injury comes from a variety of animal models (see Table 2
for a summary). While the majority of the studies
discussed below use various models of TBI, two make
use of intracerebral hemorrhage (IHC), which is a model
of hemorrhagic stroke. Therefore, the degree to which
the results of these two experiments are generalizable to
TBI is open to debate. The other models used to mimic
TBI; cryoinjury, controlled cortical impact (CCI) and
standardized weight drop, also vary in their ability to
mimic various aspects of TBI. For example, while
cryoinjury induces cerebral edema and BBB comprom-
ise, both of which are features of TBI [76], the mechan-
ism of injury is not mechanical as in TBI. In contrast,
standardized weight-drop models more faithfully mimic
the mechanical injury seen in TBI, but they have the
disadvantage of low reproducibility/reliability [77].
Therefore, the applicability of these models to human
TBI is debatable, and the interpretation of results ob-
tained using such models in the context of human TBI
should only be done with great care. CCI, like standard-
ized weight-drop models, mimics the mechanical mech-
anism of injury of TBI, and has the advantage over other
TBI models of versatility, such that the depth and
velocity of the impact can be controlled more easily. The
results are therefore more highly reproducible [77].
Moreover, the pathological changes seen with this model
closely mimic those seen in TBI itself [78]. Therefore,
results obtained using this model may be more applic-
able to humans, but care should still be taken even when
drawing conclusions from studies based on this model.
The earliest animal study investigating the involvement
of the complement system in TBI secondary injury in-
volved the administration to rats of soluble complement
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receptor 1 (sCR1), which, by suppressing C3 convertase
formation, inhibits the classical, lectin and alternative
complement activation pathways. Rats treated with sCR1
had reduced brain neutrophil infiltration compared to
vehicle-treated rats, suggesting that complement plays a
pivotal role in the neuroinflammatory response induced
by TBI. [79] These findings were supported by studies per-
formed on C3 null (C3−/−) mice. When these mice were
exposed to an ICH injury, reduced leukocyte infiltration,
microglial activation and edema build-up were observed
in the penumbral region surrounding the site of injury,
when compared with control mice. This was paralleled by
a reduced motor deficit in the affected limb compared to
controls [80]. Similar results were obtained with C3 null
mice exposed to cryoinjury [81]. In a CCI model of TBI,
C3−/− mice were found to have reduced brain leukocyte
infiltration compared to wildtypes, but there were no
differences between them with regard to injury size or
neurological deficits [82]. CNS-restricted overexpression
of complement receptor type 1-related protein y (Crry),
which inhibits C3 convertase formation, resulted in better
neurological outcomes when compared with control mice,
even up to 4 weeks after the initial injury [83]. Based on
these results, recombinant Crry (Crry-Ig) was adminis-
tered to mice that had undergone a form of closed head
injury. Reduced tissue loss as well as improved neuro-
logical outcomes was found in these mice, compared with
vehicle-treated mice that had undergone the same type of
injury, when Crry-Ig was administered 1 and 24 h after
the initial injury [84].
Animal models have also been used to investigate the
role of the anaphylatoxins (i.e. C3a and C5a) in TBI sec-
ondary injury. Interfering with the function of C5a, e.g. in
C5 null (C5−/−) mice or by administering an antagonist of
C5aR, reduced secondary damage in a cryoinjury model of
TBI [81]. Furthermore, administration of another C5aR
antagonist, [hexapeptide-derived macrocycle AcF (OPd-
ChaWR)], in an ICH model was found to improve spatial
memory (as measured by performance in the Morris water
maze) as well as general neurological function, when com-
pared with vehicle-treated controls. This was paralleled by
a reduction in leukocyte infiltration and edema in the
vicinity of the lesion [85]. When the C5aR antagonist was
combined with a C3aR antagonist, SB290157, a synergistic
neuroprotective effect was observed [85]. However, the
fact that SB290157 can also function as a C3aR agonist in
particular cells, thought to have a high density of C3aRs,
complicates the interpretation of the aforementioned
result [86, 87].
Similarly, animal studies have revealed a prominent role
for the MAC in secondary injury following TBI. The role
of the MAC was investigated using CD59 null (CD59−/−)
mice, which displayed increased MAC attachment to cell
membranes due to the absence of the MAC regulatory
protein, CD59. When these mice were exposed to a focal
closed head injury, they displayed increased neuronal loss
and worse neurological outcomes when compared to con-
trols that had undergone the same injury [88]. In contrast,
interfering with MAC formation by administrating OmCI,
a complement inhibitor that binds C5, was found to
reduce neuronal death, microglial activation and neuro-
logical deficits in a TBI mouse model when compared
with vehicle-treated controls. Administration of a C6 anti-
sense oligonucleotide, which blocks MAC formation by
inhibiting C6, yielded very similar results [89]. A recent
study building on these findings generated an inhibitor of
MAC complex formation, composed of complement
receptor of the Ig superfamily (CRIg) fused with CD59
(CD59-2a-CRIg). Administration of this inhibitor to a TBI
mouse model was found to reduce MAC formation, neur-
onal damage and microglial activation compared to
vehicle-treated controls. Paralleling this, it was found that
neurological outcomes were significantly better in the
mice treated with this inhibitor when compared with
placebo-treated mice [90].
Animal studies focusing on specific complement
activation pathways
Attempts to tease out the relative contributions to TBI
secondary injury of the different complement activation
pathways have been made using animal models [76] (see
Table 2 for a summary). Mice lacking fB (fB−/−), whose
alternative pathway of complement activation is non-
functional, were found to have reduced neuronal loss with
concomitant upregulation of the anti-apoptotic regulatory
protein Bcl-2 and downregulation of the pro-apoptotic
Fas receptor, compared with control mice subsequent to
TBI [91]. Extending this, a study investigated the effect a
monoclonal antibody directed against fB (mab1379) had
when administered to control mice, which were exposed
to a TBI-like injury, 1 or 24 h after injury. These mice dis-
played reduced neuronal loss, an attenuated inflammatory
response, as well as upregulation of genes associated with
neuroprotection when compared with vehicle-treated
mice [79]. Interestingly, however, there was no difference
observed between the two groups in terms of neurological
function [92]. Experimental evidence has also implicated
both the classical and lectin pathways in the pathogenesis
of TBI. Mice lacking complement component C4 (C4−/−),
which is involved in both the classical and lectin pathways,
and wildtype mice were subjected to a CCI injury. C4−/−
mice showed decreased brain tissue damage and reduced
motor deficits, compared to wildtypes, after CCI. These
improvements were reversed if recombinant human C4
was administered to C4−/− mice. Similarly, it was found
that mice given C1-INH (which inhibits both the classical
and lectin pathways) 10 min after the initial injury devel-
oped smaller contusions and had reduced cognitive and
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motor dysfunction compared to vehicle-treated controls.
Delayed administration of C1-INH (60 min post-injury)
led to a reduction in motor dysfunction, but had no effect
on cognitive deficits or contusion size [93]. The involve-
ment of the lectin pathway in TBI has been further inves-
tigated by immunostaining for MBL-A and MBL-C in the
cortex of wildtype mice post-CCI. MBL-C immunostain-
ing was more intense 30 min post-injury, and this lasted
for a further week. MBL-A immunostaining was less
prominent. Neuronal loss in MBL-A/MBL-C knockout
(MBL−/−) mice was reduced when compared with
wildtypes 5 weeks post-injury, which was paralleled by a
reduction in sensorimotor impairment when assessed 2–
4 weeks post-lesion [75]. In contrast to this, early after a
CCI injury (6 h post-injury), increased neurodegeneration
was observed in the hippocampi of MBL−/− mice when
compared with WT mice. Neurological deficits in MBL−/−
mice were also greater than those in WT mice, when
assessed a week after injury [94]. Thus, it may be that the
lectin pathway functions in a neuroprotective capacity in
the early phase of TBI secondary injury, before switching
to a deleterious phenotype in the late phase.
The complement system and CNS repair
While activation of the complement system can have a
number of deleterious effects in the CNS, there is
evidence that it also plays a prominent role in CNS
repair, protection and regeneration [95]. For example,
the complement system has been implicated in neuro-
genesis. In the adult human, neurogenesis is believed to
take place in two brain regions: the subgranular zone
(SGZ) of the dentate gyrus (DG) of the hippocampus
(see Fig. 3) [96] and the subventricular zone (SVZ) [86,
87] (see Fig. 4). The neuroblasts generated in the SVZ
migrate, via the rostral migratory stream (RMS), to the
olfactory bulb (OB) [97, 98]. Neural precursor cells
(NPCs) have been shown to express C3aRs and C5aRs
[99]. In vitro studies have demonstrated that the applica-
tion of C3a to NPCs enhances their maturation and mi-
gration [100]. In vivo studies have also shown that
administration of a C3aR antagonist to mice results in
reduced neurogenesis in the SGZ, the SVZ and the OB.
Put together, these findings suggest a role for C3a/C3aR
in neurogenesis. Interestingly, despite the fact that SVZ
NPCs appear to express C5aRs, C5a signaling through
C5aRs was not thought to play a role in SVZ neurogen-
esis [101], although more recent evidence suggests that
C5aR1 signaling drives mouse embryonic neural
progenitor cell proliferation in the SVZ by signaling via
protein kinase C ζ (PKCζ) [102]. In contrast, comple-
ment receptor 2 (CR2), which is expressed by DG pro-
genitor cells, appears to inhibit neurogenesis. Evidence
Fig. 3 Subgranular zone (SGZ) neurogenesis in the dentate gyrus (DG) of the hippocampus of the adult human brain. Coronal section (top left)
through the human brain, illustrating the location of the hippocampus within the medial temporal lobe, and zoomed in view of the hippocampal
formation, demonstrating its structure. Illustration of the finer structural details of the hippocampal formation (bottom right), with neural stem cells
(NSCs) shown present within the SGZ. Adapted from Vescovi, Galli and Reynolds, 2006 [126]
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for this comes from CR2-deficient mice, which show in-
creased neurogenesis, whereas C3d and interferon-α
(IFN-α) (both of which bind CR2) are associated with
downregulation of neurogenesis [103].
Furthermore, evidence for a role of complement in
neurogenesis induced by brain injury has emerged from
both human and animal studies. In human TBI cases, it
was found that neural stem cell (NSC) markers were up-
regulated in the cortex surrounding the lesion compared
to controls, indicating that neurogenesis is induced in
response to TBI [104]. A comparison between C3 null
mice and control mice that were subjected to a transient
ischemic insult revealed a significant reduction in SVZ
neurogenesis 7 days post-insult in the C3 null mice. These
differences were not linked to reactive gliosis, as there was
no difference between the C3 null and control mice in that
regard [99]. Further evidence linking C3a to neurogenesis
in the context of brain injury came from experiments in
ischemic neonatal mice. C3a/GFAP mice subjected to
neonatal hypoxic ischemia (HI) demonstrated preserved
hippocampal volume and greater levels of adult born
neurons in the DG compared to wildtypes. C3a therefore
exerted a protective effect on adult neurogenesis in the
context of ischemia. Furthermore, as adults, animals
treated with C3a peptide shortly after neonatal HI demon-
strated improved memory in a cue-induced fear condition-
ing paradigm. In contrast, administration of C3a peptide
to C3aR null ischemic neonatal mice had no effect on the
aforementioned parameters [105]. Consistent with the
improvement in memory function observed with C3a
administration in wildtype mice is the finding that adult
neurogenesis in the SGZ leads to improved learning and
memory function [106–109].
A number of experiments also indicate that the com-
plement system can have neuroprotective capabilities in
the CNS [95]. Rat neurons exposed to C1q survived
longer than neurons not treated with C1q, and they had
a statistically greater number of neurites [110]. These
neuroprotective effects of C1q may be due to upregula-
tion of cytoskeletal genes involved in synaptic function,
increased metabolism of cholesterol, as well as upregula-
tion of neurotrophic factors including neurotrophin 3
and nerve growth factor (NGF) [111]. Exposure of C5-
deficient mice to kainic acid (KA), which can act as an
excitotoxin (with excitotoxicity being one of the likely
mechanisms of secondary injury in TBI), resulted in
greater neuronal death than in wildtype mice exposed to
the same insult [112]. Thus, it appears that C5 may play
a role in protecting neurons against death by excitotoxi-
city. A further study demonstrated that it is the C5a
fragment, more specifically, that plays an important
neuroprotective role. Administration of C5a with KA
was found to result in reduced neuronal death when
compared with KA alone. Further analysis suggested that
C5a achieves this via a signalling cascade that results in
caspase-3 downregulation, thereby reducing apoptotic
cell death [113]. C3a appears to have similar neuropro-
tective effects to C5a [95]. In in vitro experiments where
neuronal-astrocytic co-cultures were exposed to N-me-
thyl-D-aspartate (NMDA), which can function as an-
other excitotoxin, concomitant application of human
C3a resulted in reduced neuronal death relative to
NMDA application alone. This neuroprotective effect,
while facilitated by C3a, appeared to be mediated by the
astrocytes, as it was abrogated in pure neuronal cultures
(i.e. in the absence of astrocytes) [114]. While the MAC
complex at higher concentrations promotes cell lysis, it
appears to have neuroprotective properties at sublytic
concentrations [95]. It can promote the survival of oligo-
dendrocytes within the CNS by inhibiting their apop-
tosis. It was found that this effect was mediated
secondary to inhibition of pro-apoptotic factors (e.g.
caspase-3) and converse activation of anti-apoptotic
factors (e.g. Bcl-2) [115]. Enhanced oligodendrocyte
survival should reduce the extent of demyelination
subsequent to an injury to the CNS, thereby aiding in
the maintenance of axonal integrity. Pharmacological
inhibition of phosphoinositide 3-kinase (PI3K) was
found to partially reverse the pro-survival effect of subly-
tic concentrations of MAC on oligodendrocytes, which
suggests that such concentrations of MAC may mediate
these effects via a PI3K signaling pathway [116].
Furthermore, CNS glia, including microglia and astro-
cytes, secrete a number of neurotrophic factors in response
to stimulation by complement components [95]. Consistent
with this, astrocytes are known to produce NGF subse-
quent to CNS injury, in response to complement compo-
nents (C3a and C5a) as well as cytokines (interleukin-1β)
[117, 118]. Similarly, C3a has been shown to induce NGF
production by microglia [119]. NGF is known to promote
Fig. 4 Neurogenesis in the subventricular zone (SVZ). Sagittal section
through the rodent brain, illustrating how NSCs generated in the SVZ
migrate via the rostral migratory stream (RMS0 to the olfactory bulb
(OB)). As the cells migrate towards the OB, they undergo terminal
differentiation. Adapted from Abrous, Koehl and Moal, 2005 [127]
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the survival of neurons (including cholinergic neurons)
subsequent to axotomy, as well as promoting sprouting and
regeneration [120]. In addition to its role in promoting
neuronal regeneration, complement has been implicated in
promoting not only just oligodendrocyte survival, but also
proliferation, subsequent to CNS injury [121]. The mechan-
ism appears to involve sublytic doses of the MAC inducing
the oligodendrocyte cell cycle [122], by inducing an array of
mitogenic and anti-apoptotic signaling pathways [123, 124].
Enhanced oligodendrocyte proliferation would be expected
to enhance neuronal myelination, thereby contributing to
the maintenance of axonal integrity. Experiments compar-
ing C5-deficient to C5-sufficient experimental autoimmune
encephalomyelitis (EAE) mice, a multiple sclerosis (MS)
model, have lent support to this notion. C5-deficient mice
displayed marked reactive gliosis and Wallerian degener-
ation of axons. This was in stark contrast with C5-sufficient
mice that were found to have significantly reduced Waller-
ian degeneration linked to concurrent remyelination and
reduced gliosis [125]. Therefore, C5 appears to play an
important facilitatory role in remyelination subsequent to
brain injury, which can contribute to improved neuronal
survival.
Future perspectives
A lot of progress has been made, over the past 30 years
or so, in determining the role the complement system
plays in TBI secondary injury. However, a multitude of
questions that must be addressed by future research re-
main. The complement system can have both neurotoxic
effects as well as neuroprotective influences subsequent
to CNS injury. While the complement system appears to
play a role in neurogenesis and promoting neuronal
survival, including subsequent to CNS injury (e.g. in the
context of excitotoxicity and experimental MS), there
are few studies that have investigated this in the context
of TBI secondary injury. A goal of future research
should, therefore, be to address directly whether comple-
ment is involved in promoting neurogenesis and neuro-
protection subsequent to TBI, e.g. by investigating this
in animal models of TBI (e.g. standardized weight-drop
and CCI models) as well as human TBI patients. If there
is indeed evidence for a neuroprotective role of comple-
ment in TBI, then it may be possible to manipulate the
complement system (e.g. pharmacologically) to promote
neurogenesis/regeneration, which may in turn amelior-
ate the disabilities that often result from TBI. Comple-
ment may play a part in mediating plasticity after TBI,
as it is known to have a developmental role in synaptic
pruning, but this has not been investigated either in
human TBI patients or in animal models of TBI. Thus, a
future goal would be to address this, as this could
provide another future target for manipulation in order
to improve neurological outcomes after TBI. It would
also be instructive to carry out studies that are designed
to assess a greater number of endpoints, as certain com-
plement components may function neuroprotectively
early on during secondary injury but may then switch to
become harmful, or vice versa. Therefore, it would be
important to ascertain timelines for the actions of the
different complement components, in order to work out
how best to manipulate them (i.e. whether to activate
them or inhibit them) and when best to do so (i.e.
whether early or late in the course of the secondary
injury). Finally, while attempts have been made using
animal models to disentangle the influences of each of
the complement activation pathways in TBI, more stud-
ies (including ones in human patients) will be required
in order to shed more light on the contributions each
makes to the pathophysiology of TBI.
Clinical and translational perspective
Based on current evidence in the literature, which has
mainly focused on the deleterious effects of complement
in the context of TBI, it appears that complement func-
tions in a mainly damaging fashion in TBI. As discussed
in the section entitled ‘The complement system and CNS
injury’, dampening down the activity of the complement
system, by various means in animal models of TBI, has
been generally associated with reduced lesion sizes as well
as improved neurological outcomes. Thus, it would appear
that a promising future strategy for TBI management
would be to target the complement system for downregu-
lation, e.g. by administering pharmacological antagonists
of various known mediators in the complement pathway.
While pre-clinical studies performed in animal models
have yielded promising results (with a number of thera-
peutics, e.g. sCR1, Crry-Ig, and SB290157, displaying some
efficacy), further experiments are required to determine
which pharmacological agents would be most appropriate,
what doses they must be administered at, via which
route(s) they must be administered, and when after the
initial injury it would be best to administer them. Subse-
quent to that, human trials must be started in order to
determine whether such agents would be both safe and
useful in the target patient group.
Conclusion
TBI is a leading cause of morbidity in the western world.
While healthcare advancements have resulted in a reduc-
tion in mortality associated with TBI, it is still a major
cause of disability. Neurological outcomes subsequent to
TBI are significantly influenced by the secondary sequelae
that follow the initial injury. The secondary injury is
multifaceted, involving a prominent neuroinflammatory
response, in addition to ischemia, excitotoxic neuronal cell
death, and free radical production. An important part of
the ensuing inflammatory response is activation of the
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complement cascade. The complement system can have
both neurotoxic and neuroprotective effects subsequent
to CNS injury. As it takes time for the secondary sequelae
of TBI to develop and for any resulting changes to become
irreversible, this may provide a window of opportunity for
interventions that may improve outcomes subsequent to
TBI. One promising target for such interventions is the
complement system. Pharmacological agents targeting
components of the complement system have been trialed
in animal models, with some promising results. Pending
further investigations, it may be possible to translate such
agents to clinical practice in the future, which may
revolutionize the management of TBI.
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